GlobeNewswire, Health, Pharmaceuticals & Biotechnology, Product / Services Announcement | Ziihera is the first and only dual HER2-targeted bispecific ...

Initially, he was diagnosed with biliary colic and treated with antibiotics and analgesics, but his symptoms worsened. A CT ...

PBC patients receiving linerixibat saw statistically significant improvement in cholestatic pruritus - or relentless itch.

GSK plc GSK announced positive headline data from the phase III GLISTEN study, which is evaluating its investigational ...

GSK announces positive results from GLISTEN phase III trial of linerixibat in adults with cholestatic pruritus (relentless itch) associated with PBC: London, UK Wednesday, Novembe ...

Interim results from the ongoing GLISTEN trial of linerixibat, GSK's targeted inhibitor of the ileal bile acid transporter ...

British drugmaker GSK said on Tuesday its experimental therapy, linerixibat, met its main goal in a late-stage trial to treat ...

INTEGRIS-PSC featured in an oral late breaker presentationSOUTH SAN FRANCISCO, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, ...

Ipsen presents three late-breaking presentations and eight abstracts across rare cholestatic liver disease portfolio at AASLD 2024Elafibranor was granted marketing authorisation for the treatment of ...

KDEV) today announces that its portfolio company Umecrine Cognition will present data from a recent interim analysis from an ongoing Phase 1b/2a clinical study of golexanolone in patients with Primary ...

"We know from our work with patient communities that receiving a diagnosis of PFIC and ALGS can be overwhelming in a patient or caregivers' life. Disease symptoms like severe itch can have an impact ...

Thanks to the living donor program at Children's Hospital Colorado, a Texas girl found a match for a new liver.